How Does Pegozafermin Work? Mechanism of Action in the Published Research

The short answer from the pharmacology literature

Pegozafermin is an investigational medicine studied in clinical trials, and the pharmacology literature describes it as a glycoPEGylated analogue of fibroblast growth factor 21 (FGF21) that activated human FGF receptors in laboratory assays and altered metabolic and liver measures in diabetic monkeys and healthy human volunteers, as researchers reported in a 2023 pharmacology paper (PMID 37562970). Reviews of metabolic drug development place it within the FGF21 analogue class being evaluated for metabolic dysfunction-associated steatohepatitis (MASH) and for severe hypertriglyceridemia (PMID 37889055). This page summarises mechanism as described in published sources and separates what has been directly measured from what remains proposed.

The receptor target: FGF receptors plus beta-klotho

FGF21 belongs to the endocrine branch of the fibroblast growth factor family, and reviews of its molecular biology describe signalling that requires both a classical FGF receptor and the membrane co-receptor beta-klotho to form a productive complex (PMID 41198096). Because beta-klotho expression is concentrated in a limited set of tissues, including adipose tissue, liver and parts of the central nervous system, that co-receptor requirement is the feature most often described as giving FGF21 biology its tissue selectivity (PMID 41198096).

In the 2023 pharmacology study, researchers reported that pegozafermin activated human FGF receptors in receptor level assays, consistent with the engineered analogue retaining the receptor engagement properties of the native hormone (PMID 37562970). Those receptor experiments were cell based work, and the usual caveat for in vitro pharmacology applies: receptor activation in a dish establishes target engagement, while tissue level consequences were examined separately in animal and human arms of the same study (PMID 37562970).

Why the receptor subtype matters

Reviews of MASH drug targets group FGF21 analogues with FGF19 analogues and thyroid hormone receptor beta agonists as agents acting on nuclear or growth factor signalling rather than on appetite pathways alone (PMID 40590228). Within that grouping, the FGF21 arm is described as acting through the c-splice variants of FGF receptors, a distinction that separates endocrine FGF signalling from the paracrine FGF signalling associated with cell proliferation (PMID 41198096).

Protein engineering: what glycoPEGylation changes

Native FGF21 is short lived in circulation, and the stated rationale for analogue development is to extend exposure so that receptor signalling can be sustained between administrations, as discussed in reviews of emerging metabolic therapies (PMID 37889055). The 2023 study described pegozafermin as a glycoPEGylated FGF21 analogue, meaning a polyethylene glycol chain is attached through a glycan linker rather than through random chemical conjugation (PMID 37562970).

The practical point reported for this design is pharmacokinetic rather than pharmacodynamic: the molecule is intended to resist rapid clearance and proteolysis while preserving the receptor binding surface, and the study evaluated receptor activity alongside outcomes in monkeys and in healthy volunteers (PMID 37562970). Questions about administration intervals in any individual case belong with a prescribing clinician and with the trial protocols themselves, and no schedule is described here.

Intracellular signalling after receptor engagement

Reviews of FGF21 molecular biology describe a canonical cascade in which ligand binding to the FGF receptor and beta-klotho complex leads to receptor dimerisation, autophosphorylation of the intracellular tyrosine kinase domain, recruitment of the adaptor FRS2, and downstream activation of the RAS and ERK1/2 mitogen activated protein kinase pathway, with additional input to PI3K and AKT signalling (PMID 41198096). Those steps are drawn from FGF21 pathway biology generally rather than from pegozafermin specific experiments, and the review framing reflects that (PMID 41198096).

Transcriptional consequences described for this cascade include changes in genes governing fatty acid oxidation, glucose uptake and adipokine secretion, which reviews of FGF21 pharmacology link to the metabolic phenotype seen with analogue treatment (PMID 37889055).

Downstream physiology as described in the literature

Adipose tissue signalling

Adipose tissue is the compartment most consistently identified as a primary site of FGF21 action, because beta-klotho is abundantly expressed there, and reviews describe adiponectin release as one of the mediators proposed to carry the signal onward to liver and muscle (PMID 41198096). Reviews of pegozafermin place this adipose first model at the centre of how an FGF21 analogue is thought to influence systemic insulin sensitivity and lipid flux (PMID 37889055).

Liver fat and lipid handling

In MASH focused reviews, FGF21 analogues are described as acting on the hepatic lipid pathway by reducing de novo lipogenesis and supporting fatty acid oxidation, which is the mechanistic rationale for measuring liver fat content as an early endpoint (PMID 38301798). A systematic review and network meta-analysis of pharmacologic therapies for MASH compared agents on liver fat content reduction and included FGF21 analogues among the compared classes (PMID 39028914). A separate network meta-analysis examined comparative efficacy and safety of therapies for metabolic dysfunction-associated steatotic liver disease over 24 weeks with respect to steatosis and fibrosis measures (PMID 40211469).

Circulating triglycerides

State of the art reviews of hypertriglyceridemia treatment list FGF21 analogues among emerging options alongside apolipoprotein C-III and ANGPTL3 directed agents, grouping them by the lipoprotein pathway each one targets (PMID 40005962). A later review of current and emerging pharmacological therapies for hypertriglyceridemia covered the same landscape and described where FGF21 directed strategies sit relative to established lipid lowering drugs (PMID 42074213). A 2026 review of triglyceride lowering therapies for hepatic steatosis addressed mechanisms and efficacy across those classes and the overlap between plasma triglyceride handling and liver fat (PMID 42206171).

Fibrosis: the proposed arm of the mechanism

Reviews of MASH pathogenesis describe fibrosis as the product of stellate cell activation driven by lipotoxicity, inflammatory signalling and injury, with drug classes assessed on whether they interrupt those upstream drivers (PMID 38672181). A systematic review and network meta-analysis compared pharmacological therapies in MASH specifically on fibrosis regression and MASH resolution, the two histological endpoints used in that field (PMID 39903735). Reviews of therapeutic horizons in MASH treat antifibrotic effects of metabolic agents as an area still being mapped rather than a settled mechanism (PMID 40590228).

Animal and early human pharmacology

The most directly relevant pegozafermin specific dataset in the verified literature is the 2023 pharmacology report, in which researchers examined receptor activation, studied diabetic monkeys, and included healthy human volunteers, reporting effects on metabolic and liver outcomes across those settings (PMID 37562970). Monkey data are animal data, and healthy volunteer data describe pharmacology in people without the disease being targeted, so neither substitutes for outcome trials in patient populations; the study design itself reflects that staged approach (PMID 37562970).

Established mechanism compared with proposed mechanism

How mechanism connects to the endpoints used in trials

Mechanistic reasoning explains why particular endpoints were chosen rather than predicting their results. Because the pathway is described as acting on hepatic lipid handling, imaging based liver fat content became an early readout, and a network meta-analysis compared therapies on exactly that measure (PMID 39028914). Because regulators focus on histology in MASH, a separate network meta-analysis compared agents on fibrosis regression and MASH resolution (PMID 39903735). Because FGF21 biology also touches plasma lipoproteins, triglyceride endpoints appear in the hypertriglyceridemia literature covering this class (PMID 42074213).

Tolerability in Trials: What Studies Report

Comparative safety across MASH and steatotic liver disease therapies was assessed in a 24 week network meta-analysis that evaluated efficacy and safety together across drug classes (PMID 40211469). The 2023 pharmacology study included healthy human volunteers in its evaluation of pegozafermin, which is the stage at which initial human tolerability signals are generated (PMID 37562970). Event level tables sit in primary trial publications and in regulatory review documents, and a prescribing clinician is the appropriate source for how any reported event applies to an individual.

Regulatory status in plain terms

Pegozafermin is described across the cited reviews as an investigational agent progressing through clinical trials in MASH and in severe hypertriglyceridemia, evaluated alongside other candidates in those fields (PMID 37889055, PMID 40005962). Its availability therefore sits within the clinical trial and regulatory review system, and treatment decisions in any disease state remain with licensed physicians working from current labelling and trial data (PMID 40590228).

Questions a prescribing clinician can address

• Whether an FGF21 directed mechanism is relevant to a specific metabolic or hepatic diagnosis, in light of comparative evidence across drug classes (PMID 39903735).
• How investigational status and trial eligibility affect access at a given moment (PMID 37889055).
• How liver fat, fibrosis staging and triglyceride measures are interpreted in context (PMID 42206171).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, diagnosis or treatment decision. For background on the compound itself, see the pegozafermin overview.

References

• The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers (The Journal of Pharmacology and Experimental Therapeutics, 2023)
• Pegozafermin Is a Potential Master Therapeutic Regulator in Metabolic Disorders: A Review (Cardiology in Review, 2025)
• Role of FGF21 in Heart Failure: Molecular Insights and Therapeutic Implications (Cardiology in Review, 2025)
• Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review (Pharmaceuticals, 2025)
• Current and Emerging Pharmacological Therapies for Hypertriglyceridemia (International Journal of Molecular Sciences, 2026)
• Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives (Frontiers in Pharmacology, 2026)
• NAFLD and NASH: etiology, targets and emerging therapies (Drug Discovery Today, 2024)
• NAFLD in the 21st Century: Current Knowledge Regarding Its Pathogenesis, Diagnosis and Therapeutics (Biomedicines, 2024)
• Therapeutic horizons in metabolic dysfunction-associated steatohepatitis (The Journal of Clinical Investigation, 2025)
• Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis (Hepatology, 2025)
• Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis (Hepatology, 2026)
• Comparative efficacy and safety of pharmacologic therapies for metabolic dysfunction-associated steatotic liver disease over 24 weeks in reducing liver steatosis and fibrosis: A network meta-analysis (Diabetes, Obesity & Metabolism, 2025)